Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication¹ in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio’s new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML).

According to the publication’s authors: “Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings.”

Ilan Danieli, CEO of Precipio, expanded on these findings. “Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all four clinically important variants of BCR::ABL1 (isoforms). Precipio is first to apply the International Scale to create a novel assay quantifying all four variants, setting a new standard for monitoring patients with CML. Now, for the first time, clinicians can comprehensively monitor disease progression.”

The study analyzed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML, and underscores the key advantage of a single assay that delivers multiple, medically relevant data points simultaneously. The assay can be run in physician office laboratories, regional laboratories and hospitals.

Key findings in the study highlight significant advantages of the assay

1.   Multiple data points lead to better decision making

The study demonstrates that 25% of patients have multiple forms of BCR::ABL1 breakpoints that are missed because looking for all four requires laboratories to run four different assays (isoforms p190, p210, p230 and p203). No other test delivers all results from the same platform at the same time.

2.   Full Quantification establishes a new standard

Quantitative results for BCR::ABL breakpoints are crucial for the management of CML, providing clinicians a precise, standardized measurement of the disease burden, thereby enabling them to monitor the impact of treatment and detect early relapse.

Current assays on the market provide quantitative results only for one breakpoint, p210 (also called “Major transcript”), using an established International Standard (IS) scale. The absence of quantified results for all four breakpoints hinders clinicians' ability to adequately monitor patients if other isoforms other than p210 indicate recurrence.

3.   High Sensitivity for MRD

Precipio’s Bloodhound BCR::ABL assay can detect changes as low as 1 in 100,000 cells (0.001%), thereby making it a powerful tool for monitoring measurable residual disease (MRD). At these low levels, early trends in these isoforms can provide months of advanced warning time that other, less sensitive or qualitative assays may not detect.

Assay introduces new testing capabilities for laboratories

The diagnosis and therapeutic decision-making in CML depend on the detection and quantification of BCR::ABL1. Until now, no clinical assay existed that could simultaneously test multiple BCR::ABL1 isoforms and provide quantified results, therefore requiring laboratories to run separate tests for each isoform.

To address this challenge, Precipio developed the BloodHound assay, enabling laboratories to provide proper, comprehensive testing for CML patients. The assay runs all 4 breakpoints on a single, pre-plated plate run (with all controls provided) on a RT-PCR machine. Precipio’s custom-developed analysis software provides fully quantified automated results including molecular response criteria. The BCR::ABL1 test provides important diagnostic criteria for patients with AML, ALL and MPN.

The new Precipio test simplifies workflow into one assay, is standardizable across laboratories, is quantitative and, importantly, provides target genetic markers to enable monitoring disease for years over the treatment course.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

______________________________

¹ PMID: 41506866 DOI: 10.1136/jcp-2025-210447

Inquiries:investors@precipiodx.com+1-203-787-7888 Ext. 523